HL1113
/ Hanlim Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 21, 2026
Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=35 | Completed | Sponsor: Hanlim Pharm. Co., Ltd.
New P1 trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1